Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

周四，在Krystal Biotech（纳斯达克代码：KRYS）于2月19日公布2024年财务业绩后，H.C.

英为财情Investing.com - Krystal Biotech (NASDAQ: KRYS )星期三发布了第四季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$1.52，总营收为$91.14M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$91.63M，每股收益为$1.21.

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price ...

South Side-based biotechnology firm Krystal Biotech Inc.'s stock is up 20% following its earnings call this morning.

Reports Q4 revenue $91.1M, consensus $91.35M. “Last year, our commercial and financial strength allowed us to deliver significant earnings ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as Vyjuvek gains traction in the U.S. market. In the year-ago quarter ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) rose 7.1% during mid-day trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup ...